Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Cell Dev. Biol., 28 August 2025

Sec. Cancer Cell Biology

Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1672461

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway

This article is a correction to:

  1. PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway

    1. Read original article
Huafu Li,,,&#x;Huafu Li1,2,3,4†Chunming Wang,&#x;Chunming Wang1,4†Linxiang Lan,&#x;Linxiang Lan2,3†Wenhui Wu&#x;Wenhui Wu1†Ian Evans,Ian Evans2,3E. Josue Ruiz,E. Josue Ruiz2,3Leping YanLeping Yan5Zhijun ZhouZhijun Zhou6Joaquim M. Oliveira,Joaquim M. Oliveira7,8Rui L. Reis,Rui L. Reis7,8Zhenran HuZhenran Hu6Wei ChenWei Chen1Axel Behrens, Axel Behrens2,3*Yulong He, Yulong He1,4*Changhua Zhang Changhua Zhang1*
  • 1Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China
  • 2Adult Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
  • 3The Institute of Cancer Research, London, United Kingdom
  • 4Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • 5Center of Scientific Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China
  • 6Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
  • 73B’s Research Group, I3Bs – Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, Guimarães, Portugal
  • 8ICVS/3B’s – PT Government Associate Laboratory, Guimarães, Portugal

A Corrigendum on
PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway

by Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y and Zhang C (2021). Front. Cell Dev. Biol. 9:719192. doi: 10.3389/fcell.2021.719192

There was a mistake in Figures 2, 4 as published. The wrong images were erroneously used for Figures 2G, 4A. The corrected Figures 2, 4 appear below.

Figure 2
Microscopic images displaying DAPI and PARP1 staining for four samples labeled GC1(OXA), GCR1(OXA), GC2(OXA), and GCR2(OXA). Each row shows separate images for DAPI staining (blue), PARP1 staining (red), and a merged view, depicting cellular and nuclear structures under different staining conditions. Each sample has two sets of images illustrating variations in staining patterns and intensity.

Figure 2. PARP1 is upregulated in oxaliplatin resistance gastric cancer. (G) Representative images of PARP1 levels stained by immunofluorescence in organoid and tumors. The scale bar represents 20 µm for tumour images, 200 µm for organoid images.

Figure 4
Four microscopic images comparing different conditions. Top left: OXA+OLP, with sparse scattered particles. Top right: OXA, showing abundant clustered particles. Bottom left: OLP, with moderate clustering. Bottom right: CON, displaying randomly distributed particles. Each panel has a scale bar.

Figure 4. PARP1 inhibition by Olaparib sensitizes gastric cancer to Oxaliplatin. (A–C) rGC1 organoids were treated with Olaparib + Oxaliplatin, Oxaliplatin, and Olaparib, respectively, before imaging (A), number of organoids (B), and size of organoids (C). The scale represents 500 µm.

The original version of this article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: gastric cancer, L-OHP resistance, homologous recombination, PARP1 inhibitors, organoid

Citation: Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y and Zhang C (2025) Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. Front. Cell Dev. Biol. 13:1672461. doi: 10.3389/fcell.2025.1672461

Received: 24 July 2025; Accepted: 08 August 2025;
Published: 28 August 2025.

Edited and reviewed by:

Ira Ida Skvortsova, Innsbruck Medical University, Austria

Copyright © 2025 Li, Wang, Lan, Wu, Evans, Ruiz, Yan, Zhou, Oliveira, Reis, Hu, Chen, Behrens, He and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Changhua Zhang, emhjaGFuZ2hAbWFpbC5zeXN1LmVkdS5jbg==; Yulong He, aGV5dWxvbmdAbWFpbC5zeXN1LmVkdS5jbg==; Axel Behrens, YXhlbC5iZWhyZW5zQGNyaWNrLmFjLnVr

†These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.